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systolic blood pressure 135 ± 18 mm Hg, eGFR 32 ± 16 mL/
min/1.73 m 2 ). The median baseline EMP count was 144/μL 
(range 10–714/μL). EMPs were numerically the highest in au-
tosomal dominant polycystic kidney disease (253 [41–610]). 
An increase in urine protein:creatinine ratio was associated 
with an increase in EMP (co-efficient 0.21,  p = 0.02). The ad-
justed HR for all-cause mortality for EMP was 8.20 (1.67–40.2, 
 p = 0.01) and for δEMP was 2.69 (0.04–165,  p = 0.64). There 
was no association between EMP or δEMP and cardiovascu-
lar events.  Conclusion: Although EMP count was a signifi-
cant marker of mortality risk, longitudinal change was not. 
This may reflect disease-specific EMP behaviour and the lim-
itation of EMP as a generalised biomarker in CKD. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) is associated with ad-
verse cardiovascular outcome. Thirty-eight percent of di-
alysis patients have evidence of coronary artery disease 
 [1] , and the life expectancy of a 25-year-old dialysis pa-
tient is 12 years compared to 52 years in the general pop-
ulation  [2] .
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 Abstract 
 Background: Chronic kidney disease (CKD) is associated 
with a unique milieu of vascular pathology, and effective 
biomarkers of active vascular damage are lacking. A candi-
date biomarker is the quantification of circulating endothe-
lial microparticles (EMPs). This study observed baseline and 
longitudinal EMP change (δEMP) and established the asso-
ciation of these with all-cause mortality and cardiovascular 
events in CKD.  Method: An observational study in adults 
with CKD (estimated glomerular filtration rate [eGFR] <60 
mL/min/1.73 m 2 ). EMPs were quantified by flow cytometry 
of platelet poor plasma in 2 samples 12 months apart and 
categorised as EMP if AnnexinV+/CD31+/CD42b– EMPs 
were compared between primary renal diagnoses, and cor-
relations between EMP/δEMP and other parameters made. 
Adjusted hazard ratios (HRs) for time to all-cause mortality 
and cardiovascular events were calculated for log-trans-
formed EMP and δEMP using a Cox proportional hazard 
model.  Results: There were 123 patients (age 63 ± 11 years, 
 It is generally agreed that this increased morbidity and 
mortality burden is not by way of “traditional” cardiovas-
cular risk factors such as hyperlipidaemia and smoking. 
As a result, biomarkers of cardiovascular disease activity 
or prognosis in CKD are often different to those seen in 
the general population. For example, lipid-lowering ther-
apy is less efficacious in CKD than the general population 
 [3] , and low serum lipids are more often a marker of mal-
nutrition than of effective therapy in advanced CKD  [4] .
 Non-atheromatous pathways to cardiovascular dis-
ease include chronic inflammation, hyperparathyroid-
ism, and endothelial dysfunction  [5–8] . CKD is associ-
ated with high circulating biomarkers of chronic inflam-
mation, such as C-reactive protein (CRP) and interleukin-6 
 [9] . However, these are not specific to vascular dysfunc-
tion. What may prove to be of greater clinical utility are
emerging biomarkers of pathological vascular endothe-
lial activity  [10–12] .
 One potential candidate is a group of circulating vesi-
cles known as endothelial microparticles (EMP). EMPs 
are membrane-bound anuclear vesicles shed by the vas-
cular endothelium in response to a number of potential 
triggers such as shear stress or inflammation  [13] . EMPs 
carry a number of activation and functional proteins, 
such as the angiogenic vascular endothelial growth factor 
and the vascular cell adhesion molecule (VCAM), which 
often reflect the underlying trigger that led to micropar-
ticle release  [14] . Elevated EMPs have been associated 
with subclinical vascular damage including increased 
aortic pulse wave velocity (PWV), increased common ca-
rotid media thickness and endothelial dysfunction  [15] . 
Elevated numbers of these particles have been reported in 
association with a number of diseases such as an increased 
risk of acute coronary syndrome and cardiovascular 
death  [16] , hypertension  [17] , pre-eclampsia  [18] and 
metabolic syndrome  [19] . EMPs also have prognostic po-
tential having been shown to correlate with clinical re-
sponse to therapy in systemic lupus erythematosus  [20] , 
and predict adverse events in otherwise stable coronary 
artery disease  [16] . In CKD, higher circulating levels of 
EMP have been found in haemodialysis patients com-
pared to pre-dialysis CKD, peritoneal dialysis and healthy 
controls  [21–23] . In haemodialysis patients, EMPs and 
other microparticles have been shown to correlate with 
arterial vascular stiffness measured by PWV and aug-
mentation index (AIx)  [24] .
 No study appears to have longitudinally measured 
EMPs in CKD, nor correlated changes in EMPs with con-
current longitudinal changes in estimated glomerular fil-
tration rate (eGFR). Alongside this, variation in levels and 
behaviour of EMPs between different primary renal diag-
noses causing CKD are not understood. This is a vital 
consideration given that CKD is a common clinical man-
ifestation of multiple disease entities rather than a singu-
lar disease state. Understanding any potential role of 
EMP as a biomarker in CKD may require disease-specif-
ic considerations.
 The aims of this study, therefore, were to explore differ-
ences in EMP count and longitudinal change in EMP 
(δEMP) between different primary renal diseases, and to 
observe the association of absolute EMP count and δEMP 
with (1) absolute and longitudinal changes in eGFR and 
other possible markers of CKD-associated cardiovascular 
risk such as hyperparathyroidism, inflammation and anae-
mia; (2) vascular stiffness as measured by AIx; and (3) long-
term clinical outcome, particularly cardiovascular events.
 Method 
 This was a sub-study of the Salford Kidney Study, a single-cen-
tre, longitudinal, observational study of patients with stage 3 to 5 
CKD referred to an adult secondary care nephrology outpatient 
clinic  [25, 26] .
 Patients 
 Patients were approached for inclusion in the study if aged >18 
years and with eGFR <60 mL/min/1.73 m 2 , and enrolled if written 
informed consent was gained. Patients were excluded from this 
sub-study if they had a history of any previous cardiovascular 
event including during the time between baseline and repeat EMP 
sampling (myocardial infarction, stroke, limb or gut ischaemia, 
coronary or peripheral revascularisation, hospitalisation for heart 
failure or symptomatic arrhythmia), or if they had a history of 
smoking. A target of 125 patients was then sought to include 25 
patients in each of 5 primary renal disease categories (c-antineu-
trophil cytoplasmic antibody [cANCA] vasculitis, IgA nephropa-
thy, diabetic nephropathy, hypertensive nephrosclerosis, autoso-
mal dominant polycystic kidney disease [ADPKD]). These were 
chosen to cover inflammatory and non-inflammatory renal dis-
ease, and proteinuric and non-proteinuric diseases. The diagnoses 
were histological in cANCA and IgA disease, based on imaging in 
APKD, and either histological or presumed diagnoses in diabetic 
and hypertensive disease. In cases diagnosed as being diabetic ne-
phropathy without biopsy, we necessitated the presence of pro-
teinuria (urine protein:creatinine ratio [uPCR] >100 g/mol) and 
diabetic retinopathy. A diagnosis of hypertensive disease without 
biopsy was made on the basis of hypertension, evidence of end-
organ damage elsewhere such as left ventricular hypertrophy on 
echocardiography, and the absence of urinary sediment or evi-
dence of an alternative diagnosis. This, we acknowledge, is a less 
robust approach than using only biopsy-proven cases, but better 
reflects real-life practice. Patients with cANCA vasculitis or IgA 
nephropathy were included only if they were on maintenance im-
munosuppression and not initiation therapy, and if antibody was 
negative at the time of consent in the case of cANCA. Twenty-five 
consecutive patients with each primary disease who met these in-
clusion and exclusion criteria were then targeted for inclusion in 
this analysis.
 Clinical Parameters 
 At the time of enrollment, patients were assessed for blood pres-
sure (BP), demographic data, Karnofsky Performance Score, past 
medical history, prescribed medication, pulse wave analysis (PWA) 
and standard biochemical laboratory profile including MDRD cal-
culated eGFR. An additional platelet poor plasma (PPP) citrate 
sample was collected and frozen at –80   °   C for EMP quantification 
in batches. All laboratory samples, including PPP, were repeated at 
a second visit after 12 months. Patients were followed up for a min-
imum of 12 months after second visit and outcome data was col-
lected by way of mortality data, including cause of death, sourced 
from the United Kingdom Office of National Statistics.
 Pulse Wave Analysis 
 PWA was assessed by applanation tonometry using a Spygmo-
Cor ® (AtCor Medical, West Ryde, NSW, Australia). The primary
measure of aortic vascular stiffness in this study was AIx corrected 
for ejection duration and heart rate. Patients underwent assessment 
after they had been recumbent for a 5 min period of rest in the same 
position. Readings were recorded from the non-dominant arm.
 PPP Preparation 
 PPP was generated by 2 step centrifuge, first at 1,700  g for 
10 min before harvesting of plasma and at 20,000  g for 20 min to 
harvest PPP. The frozen samples were thawed at room tempera-
ture for 20 min before use.  
 Flow Cytometry 
 EMP quantification was performed by flow cytometry, the de-
tailed methodology having been described previously  [20] . In 
short, PPP was incubated with phycoerythrin-conjugated antihu-
man CD31 (BD Pharminogen 55546, BD Biosciences, New Jersey, 
USA), allophycocyanin-conjugated antihuman CD42b (BD Phar-
minogen 551061, BD Biosciences, New Jersey, USA) and efluor450 
Annexin-V marker (Annexin V Apoptosis Detection Kit eBiosci-
ence, UK), with the addition of 10 μm diameter counting beads 
(Flow-Count TM Fluorospheres; Beckman Coulter, UK). Flow cy-
tometry was performed using the Beckman Coulter Cyan ADP 
flowcytometer and analysed using Summit version 4.3 software, 
with gates set to exclude artefact and beads. EMPs were considered 
microparticles (MPs) that were positive for CD31 and Annexin V 
but negative for CD42b (CD31+/AnnexinV+/CD42b– EMPs) and 
quantified as MPs per microlitres. A sample output of EMPs in the 
Summit software is found in  Figure 1 .
 Statistical Method 
 Descriptive statistics is presented as mean ± one SD for normally 
distributed continuous variables or otherwise median (range). 
 Between-group differences in EMP count and patient characteristics 
between primary renal diseases were analysed using one-way analy-
sis of variance or Kruskal–Wallis test for these parametric and non-
parametric tests respectively. The study was not specifically powered 
to explain this analysis given that it has not previously been described.
 The relationship between baseline parameters (age, BP, bio-
chemistry and AIx) and EMP count (baseline EMP and δEMP) was 
analysed using Spearman’s correlation coefficient.
 Survival analyses were performed for time to (1) all-cause mor-
tality, (2) major cardiovascular event or death, and (3) renal re-
placement therapy (dialysis or transplantation) for the study pop-
ulation as a whole. Follow-up time was from the date of collection 
of the second EMP sample. Cardiovascular events were defined as 
stroke, myocardial infarction, coronary artery intervention in-
cluding bypass graft, non-coronary revascularisation, limb ampu-
tation for ischaemic injury, or hospitalisation for heart failure. 
Analyses used a multivariate Cox proportional hazard model. 
EMP values were log transformed and δEMP values underwent af-
fine and log transformation due to the high number of negative 
values. The model included EMP, δEMP, and any other parameter 
noted to be significant on univariate analysis including demo-
graphics, co-morbidities, laboratory parameters and AIx. The haz-
ard ratios (HRs) given for EMP and δEMP are for unit change in 
log value. For this and all other analyses, statistical significance was 
set at  p < 0.05.
 Results 
 Baseline Characteristics 
 There were 123 patients. The mean age was 63 ± 11 
years, systolic BP 135 ± 18 mm Hg and eGFR 32 ± 16 mL/
min/1.73 m 2 . The diagnoses were cANCA vasculitis ( n = 
21), IgA nephropathy ( n = 25), diabetic nephropathy ( n = 
25) hypertension ( n = 26), and ADPKD ( n = 26). The over-
all median EMP count was 144/μL (range 10–714/μL).
There was a numerical but not statistical difference in
EMP count between CKD diagnoses ( Table 1 ;  Fig. 2 ), with 
ADPKD being the highest (253 [41–610]) and cANCA
vasculitis being the lowest (107 [21–610],  p = 0.06). There 
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 Fig. 1. Example of output for EMP in the Summit software. 
were statistical differences in baseline age, eGFR and Kar-
nofsky performance score between CKD groups. These 
are summarised in  Table 1 .
 Correlation of Microparticle Count with 
Other Parameters 
 In the entire CKD group, there was no statistically sig-
nificant correlation between baseline EMP count and any 
of eGFR (correlation co-efficient –0.10,  p = 0.41) age 
(0.14,  p = 0.12), CRP (–0.11,  p = 0.34), systolic BP (0.02, 
 p = 0.81), serum phosphate (0.09,  p = 0.35), serum total 
corrected calcium (–0.02,  p = 0.80), parathyroid hor-
mone (PTH; 0.09,  p = 0.32), haemoglobin (–0.12,  p = 
0.20), serum albumin (0.06,  p = 0.49), total cholersterol 
(–0.16,  p = 0.08), CRP (–0.16,  p = 0.88; uPCR, 0.01,  p = 
0.91), or aortic pulse wave AIx (0.01,  p = 0.98). There was 
a significant inverse correlation between EMP and δEMP 
(–0.559,  p < 0.01).
 The mean time between EMP measurements was 
391 ± 70 days, during which there was a median δEMP of 
+25/μL (range –689 to +1,295/μL). During follow-up, the
mean change in eGFR (δeGFR) was +1 ± 6 mL/min/1.73
m 2 . The correlation between δeGFR and δEMP was mod-
erate but statistically significant (coefficient 0.20,  p = 
0.03). There was also a significant relationship between
change in urine protein and δEMP with an increase in
uPCR being associated with an increase in EMPs (coef-Ta
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 Fig. 2. Comparison of baseline EMP count between diagnoses. 
ADPKD, autosomal dominant polycystic kidney disease. 
ficient 0.21,  p = 0.02). The correlation between δeGFR 
and δEMP retained its significance after adjustment for 
change in uPCR ( Fig. 3 ). There was no other significant 
correlation between longitudinal change in EMP count 
and change in any other measured laboratory parameter 
or AIx.
 Disease-Specific Correlations 
 The relationship between change in EMP from base-
line to follow-up and change in eGFR appeared to differ 
between diagnoses. For vasculitis and ADPKD, there 
were large positive correlations between δEMP and 
δeGFR. The respective correlation coefficients for these 
diagnoses were 0.40 ( p = 0.06) and 0.49 ( p < 0.01). For 
diabetic nephropathy and IgA nephropathy, there were 
negative correlations: –0.32 ( p = 0.12) and –0.24 ( p = 
0.29), respectively. The coefficient in hypertension was 
0.08 ( p = 0.71).
 The correlation between EMP and eGFR was not sig-
nificant when analysed by each individual primary re-
nal disease. There were very few disease-specific sig-
nificant correlations between EMP and any baseline 
laboratory parameters or AIx, and between δEMP and 
longitudinal change in any parameter. Patients with 
IgA nephropathy demonstrated a significant correla-
tion between δEMP and δuPCR (coefficient 0.557,  p < 
0.01). Patients with hypertension demonstrated a cor-
relation between EMP and age (0.525,  p < 0.01) and 
uPCR (0.509,  p < 0.01). Patients with hypertension also 
demonstrated a negative correlation between δEMP 
and both δphosphate (–0.398,  p = 0.04) and δPTH 
(–0.520,  p = 0.02).
 Survival Analysis 1: All-Cause Mortality 
 The mean follow-up period after the second EMP 
measurement was 3.9 ± 2.2 years. During this time, there 
were 32 deaths (26% of CKD patients). The leading causes 
of death were coronary artery disease ( n = 11, 34% of 
deaths) and pneumonia ( n = 7, 22%). End-stage kidney 
disease, heart failure and malignancy were each respon-
sible for 3 deaths (9% each). On univariate analysis of all-
cause mortality, EMP was statistically associated with in-
creased risk of death. The HR, for all-cause mortality with 
each unit increase in log EMP was 3.31 (95% CI 1.12–
9.76,  p = 0.03). δEMP was not significantly associated 
(HR 0.64 [0.21–1.94],  p = 0.43). Other parameters that 
were positive on univariate analysis were age, diabetes, 
Karnofsky score, eGFR, PTH, CRP, and haemoglobin. 
The results for AIx were not significant (HR 1.02 [0.97–
1.07]). Full results of the univariate analyses are found in 
 Table 2 . In the multivariate Cox regression analysis of all-
cause mortality, EMP retained its significance (HR 8.20 
[1.67–40.2]), as did age and eGFR. In this model, δEMP 
showed a numerical association with mortality, but this 
did not reach significance (HR 2.69 [0.04–165],  p = 0.64). 
The full results of the multivariate model are found in 
 Table 3 , alongside goodness of fit results for the multi-
variate model.
 Because of the strong inverse correlation between 
EMP and δEMP noted above (i.e., those patients with the 
highest baseline EMPs saw the greatest numerical fall in 
EMPs), δEMP was also analysed as a percentage change 
from baseline to follow-up sampling. In univariate analy-
sis, the affine log-transformed percentage δEMP also 
failed to reach statistical significance (HR 0.81 [0.41–
1.58],  p = 0.53).
 Survival Analysis 2: Cardiovascular Events 
 There were 22 major cardiovascular events (18%) in-
cluding 9 cardiovascular deaths (28% of deaths, 7% of pa-
tients). Age was the only parameter that demonstrated an 
association with cardiovascular outcome on univariate 
analysis (HR 1.05 [1.00–1.09],  p = 0.03). The complete 
univariate model is found in  Table 2 . Neither EMP nor 
δEMP were significant. In the multivariate survival anal-
ysis, no parameters demonstrated statistical significance. 
Indeed, the goodness-of-fit analysis itself was non-signif-
icant in this model. The results of the multivariate analy-
sis are found in  Table 3 .
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Table 2.  Univariate association of all measured parameters with each of all-cause mortality, major cardiovascular events, and  progression 
to renal replacement therapy
All-cause mortality Cardiovascular event  RRT
HR (95% CI) p value HR (95% CI) p value  HR (95% CI) p value
Age, years 1.11 (1.07–1.16) <0.01 1.05 (1.00–1.09) 0.03 0.99 (0.96–1.02) 0.49
Systolic BP, mm Hg 1.00 (0.98–1.02) 0.93 1.00 (0.98–1.02) 0.97 1.00 (0.98–1.02) 0.71
Body mass index, kg/m2 1.04 (0.97–1.12) 0.26 1.06 (0.98–1.14) 0.16 1.01 (0.94–1.08) 0.85
Diabetes 2.44 (1.17–5.07) 0.02 2.15 (0.91–5.10) 0.08 1.21 (0.54–2.71) 0.65
Heart failure 1.57 (0.21–11.56) 0.66 0.05 (0.00–3519) 0.59 0.05 (0.00–459) 0.51
Male gender 0.72 (0.34–1.49) 0.37 1.23 (0.50–3.06) 0.65 0.69 (0.34–1.40) 0.30
Karnofsky score 0.95 (0.91–0.99) 0.03 0.96 (0.91–1.01) 0.12 0.99 (0.93–1.04) 0.63
EMP count 3.31 (1.12–9.76) 0.03 0.55 (0.19–1.64) 0.28 0.97(0.38–2.46) 0.95
δEMP 0.64 (0.21–1.94) 0.43 6.04 (0.41–89.93) 0.19 0.42 (0.12–1.45) 0.17
AIx, % 1.02 (0.97–1.07) 0.41 0.98 (0.93–1.04) 0.49 0.99 (0.95–1.03) 0.62
eGFR, mL/min/1.73 m2 0.95 (0.92–0.98) <0.01 0.97 (0.93–1.00) 0.07 0.94 (0.91–0.97) <0.01
Phosphate, mmol/L 1.95 (0.50–7.64) 0.33 2.11 (0.41–10.76) 0.37 6.05 (1.38–26.4) 0.02
Corrected calcium, mmol/L 1.94 (0.12–31.74) 0.64 0.42 (0.01–15.73) 0.64 0.53 (0.03–10.1) 0.67
PTH, pmol/L 1.00 (1.00–1.01) 0.02 1.00 (0.99–1.01) 0.90 1.01 (1.00–1.01) <0.01
Albumin, g/L 0.98 (0.90–1.06) 0.57 0.99 (0.89–1.11) 0.91 0.89 (0.83–0.96) <0.01
Cholesterol, mmol/L 0.67 (0.44–1.02) 0.06 1.19 (0.77–1.83) 0.44 1.00 (0.70–1.42) 0.99
CRP mg/L 1.03 (1.00–1.06) 0.05 1.03 (0.99–1.06) 0.11 1.01 (0.98–1.05) 0.54
uPCR g/mol 1.00 (1.00–1.00) 0.66 1.00 (1.00–1.00) 0.90 1.01 (1.00–1.02) <0.01
Haemoglobin g/L 0.97 (0.95–0.99) 0.01 0.99 (0.97–1.02) 0.52 0.96 (0.94–0.98) <0.01
 HR, hazard ratio; RRT, real replacement therapy; BP, blood pressure; EMP, endothelial microparticle; δEMP, longitudinal change 
in EMP; AIx, augmentation index; PTH, parathyroid hormone; CRP, C-reactive protein; uPCR, urine protein:creatinine ratio; eGFR, 
estimated glomerular filtration rate.
Table 3.  Multivariate models demonstrating the independent association of parameters with each of all-cause mortality, major 
 cardiovascular events, and progression to renal replacement therapy
All-cause mortality Cardiovascular event  RRT
HR (95% CI) p value HR (95% CI) p value  HR (95% CI) p value
Age, years 1.12 (1.03–1.22) 0.01 1.04 (0.99–1.09) 0.12 – –
Diabetes 1.12 (0.38–3.26) 0.84 1.55 (0.61–3.97) 0.36 – –
Karnofsky score 0.99 (0.93–1.05) 0.70 – – – –
EMP count 8.20 (1.67–40.2) 0.01 0.76 (0.19–2.97) 0.69 0.72 (0.22–2.41) 0.60
δEMP 2.69 (0.04–165) 0.64 5.80 (0.22–155) 0.29 0.21 (0.04–1.22) 0.08
eGFR, mL/min/1.73 m2 0.91 (0.84–0.99) 0.03 0.98 (0.94–1.02) 0.43 0.97 (0.93–1.01) 0.10
Phosphate, mmol/L – – – – 0.71 (0.13–3.94) 0.70
PTH, pmol/L 1.00 (0.99–1.01) 0.93 – – 1.00 (1.00–1.01) 0.15
Albumin, g/L – – – – 0.90 (0.83–0.98) 0.01
Cholesterol, mmol/L 0.61 (0.28–1.31) 0.20 – – – –
CRP, mg/L 1.02 (0.99–1.07) 0.22 – – – –
uPCR, g/mol – – – – 1.00 (1.00–1.00) 0.15
Haemoglobin, g/L 0.98 (0.94–1.03) 0.39 – – 0.98 (0.95–1.01) 0.20
Goodness of fit –2LL = 107; χ2 = 27 <0.01 –2LL = 182; χ2 = 9 0.102 –2LL = 211; χ2 = 34 <0.01
 HR, hazard ratio; RRT, real replacement therapy; EMP, endothelial microparticle; δEMP, longitudinal change in EMP; AIx, 
 augmentation index; PTH, parathyroid hormone; CRP, C-reactive protein; uPCR, urine protein:creatinine ratio; –2LL, –2 log like-
lihood; χ2, chi-square.
 Survival Analysis 3: Renal Replacement Therapy 
 Thirty-one patients required renal replacement therapy 
during the follow-up period (25%). EMP and δEMP were 
not significant on either univariate or multivariate analysis. 
The results of these analyses are found in  Tables 2 and  3 , 
respectively. The only independent predictor of disease 
progression to real replacement therapy in the multivariate 
model was serum albumin (HR 0.90 [0.83–0.98],  p = 0.01).
 Discussion 
 EMP in Different Renal Diseases 
 In this study of patients with CKD but no prior cardio-
vascular or smoking history, there was a difference in base-
line EMP count for different primary renal diagnoses with 
a  p value of = 0.06. Of note, the 2 diseases with the highest 
median EMP count were ADPKD and hypertension. Al-
though EMPs may be associated with an inflammatory 
state, shear stress is a key trigger to EMP release. In turn, 
hypertension will lead to intra-vascular shear stress. The 
lower eGFR in ADPKD compared to other primary dis-
eases may also have been contributory, although there was 
no significant correlation between eGFR and EMP in this 
analysis. Furthermore, EMPs behave differently in differ-
ent disease states and so their absolute values may be dif-
ficult to interpret in the context of renal function alone. 
For example, EMPs have been noted to be elevated in type 
1 diabetes compared to controls but not in type 2 diabetes 
compared to controls in the same study  [27] . EMPs have 
also been found in high levels in severe hypertension in 
patients without CKD compared to normal controls, as 
well as in acute coronary syndrome  [16] . In these settings, 
their formation may be a response to, rather than a precur-
sor of, vascular damage. This is supported by in vitro find-
ings of EMPs promoting angiogenesis and thrombosis.
 Correlation of δEMP 
 The positive correlation between δEMP and δeGFR 
(i.e., that EMP levels increased where eGFR improved 
over time) may seem surprising. However, this is not a 
unique finding. A previous study has shown higher serum 
levels of the vascular endothelial activation markers sol-
uble intercellular adhesion molecule 1 (sICAM-1), 
 sVCAM-1 and sE-selectin in both patients with pre-dial-
ysis CKD and on dialysis when compared to normal 
eGFR controls but without a difference in level between 
CKD and dialysis groups  [23] .
 There has also been no adjustment made for pre-
scribed medication in our study. One may hypothesise 
that therapeutic interventions will affect EMP count in-
dependent of eGFR, and thereby possibly account for the 
increase in EMPs as eGFR improves. This is important 
given that different primary renal diagnoses will neces-
sitate different therapeutic approaches.
 The positive correlation between proteinuria and 
δEMP is likely to reflect that proteinuria is associated with 
disease activity in many causes of CKD, such as diabetic 
nephropathy, IgA nephropathy, vasculitis and also hy-
pertension. In the disease-specific correlation analyses, 
the most significant correlations between proteinuria and 
EMPs were in IgA nephropathy and hypertension. 
 Proteinuria is also associated with increased cardiovascu-
lar risk in CKD, and the proposed mechanisms include its 
role as a potential marker of inflammation in disease; it is 
also associated with endothelial dysfunction. These 
mechanisms, particularly the latter, are also known to be 
associated with elevated EMPs in non-CKD disease.
 The other noteworthy disease-specific correlation that 
was found was between δEMP and both δphosphate and 
δPTH (–0.520,  p = 0.02). These relationships were nega-
tive, indicating that a rise in PTH and phosphate would 
be found with a concurrent fall in EMPs. Phosphate and 
PTH are markers of CKD mineral bone disorder and 
would be expected to be associated with vascular damage 
rather than a fall in EMPs. It may be that these findings 
represent a type 1 error in view of the large number of 
correlation analyses performed.
 The Association of EMP with AIx 
 We found no correlation between baseline or longitu-
dinal change in EMP and AIx. Contrary to this, a previ-
ous study of 44 maintenance haemodialysis patients 
found a significant association between cross-sectional 
measurements (r = 0.46,  p < 0.01)  [15] . The fact that our 
study was in non-dialysis CKD may provide understand-
ing of this, as clinically significant vascular stiffness 
 becomes more pronounced with falling eGFR. Dursun 
et al.  [24] did find a relationship between EMP and vas-
cular stiffness in a cohort of CKD patients of which some 
were not on dialysis. However, these were paediatric pa-
tients and the assessment was by way of PWV. PWV is 
thought to be a better indicator than AIx of the diffuse 
medial calcification noted in vascular stiffness associated 
with CKD.
 Survival Analysis 
 We found a significant independent association of 
baseline EMP with mortality in this CKD population. 
However, despite EMP being a marker of vascular dys-
function, the significant association did not extend to 
cardiovascular events. Such an association is noted else-
where, such as in predicting cardiovascular events and 
death in patients with established coronary artery dis-
ease, and also in patients on dialysis. In a study of 81 
maintenance haemodialysis patients, each log increase 
in baseline EMP was associated with a 22-fold increased 
risk of all-cause and 20-fold increased risk of cardiovas-
cular death  [28] . Our study included patients with bet-
ter preserved eGFR in whom vascular risk would be ex-
pected to be lower, and this may account for the differ-
ence in HR for all-cause mortality, and the 
non-significance in our analysis of cardiovascular 
death.
 Our results demonstrate a striking variability in both 
baseline and longitudinal changes in EMP despite select-
ing patients with apparently stable renal disease. We ob-
served potential differences in expected EMP count be-
tween renal diseases, as well as differences between dis-
eases in the association of EMP and δEMP with other 
factors such as proteinuria and eFGR. This is reflected in 
the very wide CIs for δEMP in the multivariate survival 
analyses and the lack of statistical significance despite en-
couraging numerical HR for all-cause mortality and car-
diovascular events, which reflect the finding of other 
studies. Evidently, a far larger study would be required to 
be adequately powered to provide conclusive answers to 
whether EMPs are a useful marker of cardiovascular risk 
in early CKD and whether its utility will differ between 
causes of renal failure.
 Conclusions 
 EMP are elevated in CKD, but this appears to differ be-
tween renal diseases. The broad range of baseline EMP 
counts and δEMP create large CIs for determining what is 
“normal” EMP activity in CKD. These factors will inhibit 
the generalised utility of EMP as a biomarker of disease ac-
tivity and vascular risk in CKD. Greater evaluation of EMP 
activity in different renal diseases during the different phas-
es of the disease and at different stages of CKD is required.
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